Effects of bromodomain protein inhibition in a mouse model of Niemann-Pick type C disease
- 1Centre National de la Recherche Scientifique, Universite de Strasbourg, Institut des Neurosciences Cellulaires et Integratives, 8 allee du General Rouvillois, 6
Abstract
Defects in lysosomal lipid handling provoke fatal disorders presenting neurovisceral symptoms with variable onset and life spans. A prime example is Niemann-Pick type C disease (NPCD), where export of cholesterol and other lipids from the endosomal-lysosomal system is impaired due to variants of either NPC intracellular cholesterol transporter 1 (NPC1) or NPC intracellular cholesterol transporter 2 (NPC2). Therapeutic options for NPCD are limited to palliative care and disease-modifying drugs, and there is an unmet need for new treatments. Based on positive effects in patient-derived fibroblasts in vitro, we explored here how inhibition of bromodomain and extra-terminal domain (BET) proteins, a family of histone acetylation readers, affects a well-established mouse model bearing the frequent I1061T variant of NPC1. To this end, we used employed intraperitoneal administration of the blood-brain-barrier penetrating drug JQ1 or vehicle (dimethylsulfoxide), and gauged drug effects based on weight, biomarker levels and quantitative assessment of motor coordination.Treatment of mice with JQ1 induced beneficial effects on some outcome measures, notably a transient increase in weight, reduction of liver cholesterol, and improvements in the footprint test, but these effects occurred only in male but not in female mice. Our results indicate bromodomain proteins as potential therapeutic drug target for NPCD and reveal sex-dependent BET protein signaling in mice.
Related
- Pharmacological BET Protein Inhibition Reverts Niemann-Pick Type C Disease-Associated Changes in Human iPSC-Derived Cortical Neurons
- Cell-cycle inhibition preserves robust development but rebalances lineages in mouse gastruloids
- Factor H polymorphism elevates granzyme B and impairs complement inhibition in human and mouse models
- VCP inhibition prevents cone photoreceptor degeneration in the cpfl1 mouse model of achromatopsia
- Inhibition of Parasite Protein Kinase C by New Antileishmanial Imidazolidin-2-one Compounds
BibTeX
@misc{parente2026effects,
title = {{Effects of bromodomain protein inhibition in a mouse model of Niemann-Pick type C disease}},
author = {M. Parente and A. Barthelemy and S. Caputo and N. Charlery-Adele and C. Galmiche and C. Tonini and S. Lobasso and D. Prtvar and S. W. Tahirovic and S. Reibel and F. W. Pfrieger and V. Pallottini},
howpublished = {bioRxiv},
year = {2026},
month = jun,
doi = {10.64898/2026.06.24.734200},
url = {https://www.biorxiv.org/content/10.64898/2026.06.24.734200v2},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Effects of bromodomain protein inhibition in a mouse model of Niemann-Pick type C disease
AU - M. Parente
AU - A. Barthelemy
AU - S. Caputo
AU - N. Charlery-Adele
AU - C. Galmiche
AU - C. Tonini
AU - S. Lobasso
AU - D. Prtvar
AU - S. W. Tahirovic
AU - S. Reibel
AU - F. W. Pfrieger
AU - V. Pallottini
PY - 2026
DA - 2026/06/24
PB - bioRxiv
DO - 10.64898/2026.06.24.734200
UR - https://www.biorxiv.org/content/10.64898/2026.06.24.734200v2
AB - Defects in lysosomal lipid handling provoke fatal disorders presenting neurovisceral symptoms with variable onset and life spans. A prime example is Niemann-Pick type C disease (NPCD), where export of cholesterol and other lipids from the endosomal-lysosomal system is impaired due to variants of either NPC intracellular cholesterol transporter 1 (NPC1) or NPC intracellular cholesterol transporter 2 (NPC2). Therapeutic options for NPCD are limited to palliative care and disease-modifying drugs, and there is an unmet need for new treatments. Based on positive effects in patient-derived fibroblasts in vitro, we explored here how inhibition of bromodomain and extra-terminal domain (BET) proteins, a family of histone acetylation readers, affects a well-established mouse model bearing the frequent I1061T variant of NPC1. To this end, we used employed intraperitoneal administration of the blood-brain-barrier penetrating drug JQ1 or vehicle (dimethylsulfoxide), and gauged drug effects based on weight, biomarker levels and quantitative assessment of motor coordination.Treatment of mice with JQ1 induced beneficial effects on some outcome measures, notably a transient increase in weight, reduction of liver cholesterol, and improvements in the footprint test, but these effects occurred only in male but not in female mice. Our results indicate bromodomain proteins as potential therapeutic drug target for NPCD and reveal sex-dependent BET protein signaling in mice.
ER -